Viking Therapeutics witnessed a significant boost in its share price following the release of compelling data from a mid-stage clinical study. The biopharmaceutical company presented an exploratory analysis from its Phase 2 VENTURE trial for drug candidate VK2735 during the ObesityWeek® 2025 conference. These results, which substantially surpassed market expectations, have reinvigorated investor sentiment toward the stock.
Market Responds to Encouraging Obesity Treatment Findings
The latest data for VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated remarkable efficacy in addressing obesity-related metabolic conditions. Patients with prediabetes and metabolic syndrome showed exceptional progress after just 13 weeks of treatment.
Investors reacted positively to this development, driving Viking Therapeutics shares upward by 2.19% during the most recent trading session. The equity displayed considerable movement throughout the day, fluctuating within a 6.74% range between its peak and lowest price points.
Quantifiable Clinical Benefits Drive Investor Confidence
The trial outcomes revealed measurable therapeutic advantages that extend well beyond simple weight reduction metrics:
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
-
Reversal of Prediabetes: A substantial 78% of prediabetic patients receiving VK2735 treatment achieved normalized blood glucose levels, compared to only 29% in the placebo control group.
-
Metabolic Syndrome Resolution: Among treated participants, 68% no longer met the diagnostic criteria for metabolic syndrome after the 13-week study period. This contrasts sharply with the 38% rate observed in the placebo cohort.
Positive Data Offsets Previous Quarterly Performance
These comprehensive clinical findings provide renewed momentum for Viking Therapeutics stock following a disappointing third-quarter earnings report where per-share profits fell short of projections. The robust data presented at this prominent medical conference signals a potential inflection point for the company. Enrollment for Phase 3 trials is reportedly progressing faster than anticipated, while these strong Phase 2 results substantiate the advancement of the company’s obesity medication development program.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from November 8 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 8.
Viking Therapeutics: Buy or sell? Read more here...
